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Scalp acupuncture (SA) is a commonly used therapeutic approach for stroke throughout China and elsewhere in the world. The
objective of this study was to assess clinical eﬃcacy and safety of SA for acute ischemic stroke. A systematical literature search
of 6 databases was conducted to identify randomized controlled trials (RCTs) of SA for acute ischemic stroke compared with
western conventional medicines (WCMs). All statistical analyses were performed by the Rev Man Version 5.0. Eight studies with
538 participants were included in the studies. The studies were deemed to have an unclear risk of bias based on the Cochrane
Back Review Group. Compared with the WCM, 6 RCTs showed significant eﬀects of SA for improving neurological deficit scores
(P < 0.01); 4 RCTs showed significant eﬀects of SA for favoring the clinical eﬀective rate (P < 0.01) However, the adverse events
have not been documented. In conclusion, SA appears to be able to improve neurological deficit score and the clinical eﬀective rate
when compared with WCM, though the beneficial eﬀect from SA is possibly overvalued because of generally low methodology of
the included trials. No evidence is available for adverse eﬀects. Rigorous well-designed clinical trials are needed.
1. Introduction
Stroke is the second most common cause of death preceded
only by heart attacks and the major cause of disability in the
Western world [1] and may soon become the leading cause
of death worldwide [2]. More than two thirds of the burden
of global stroke occurs in developing (low- and middle-
income) countries [3]. Ischemic stroke is the most common
subtype of stroke, accounting for about 80% of all strokes.
Moreover, the epidemiological data showed that from 1984
to 2004 the incidence of ischemic stroke increased by 8.7%
though the incidence of hemorrhagic stroke decreased by
1.7% every year in China [4]. Therefore, prevention and
treatment of stroke, especially ischemic stroke in China has
become an even greater challenge than that in the developed
countries. However, the optimization of modern clinical
treatment with acute ischemic stroke was only an integrated
and systematic approach with thrombolysis, if indicated,
and aggressive supportive care [5]. Thrombolysis agents,
such as recombinant tissue plasminogen activator (rt-PA),
were indicated for ischemic stroke if administered within
4.5 hours of stroke onset. However, bleeding risk, mortality
rate (evident at 7 to 10 days and at final followup), and the
incidence of intracranial haemorrhages have been reported
to increase with the use of thrombolytic agents [6]. Thus,
complementary and alternative medicine (CAM) therapies
are increasingly used in patients with stroke adjunct to
conventional treatment.
The most appreciable distinction between China and
the West in treating stroke is the application of traditional
Chinese medicine (TCM) which includes herbal medicine,
acupuncture, and other nonmedication therapies [7, 8].
Acupuncture has been used in many diseases, especially in
stroke victims, as a medical modality for over 3000 years
[9]. In modern time, at least 9 systematic reviews and
meta-analysis have been conducted in the eﬀectiveness and
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safety of acupuncture for stroke [10]. Among of them, 1
focused on acute stroke; 1 focused on subacute and chronic
stroke; 5 observed the variable interval after stroke onset;
and 2 addressed dysphagia after stroke. However, the results
regarding the eﬀectiveness of acupuncture for stroke recovery
were inconclusive. Especially, the review from Kong and
colleagues [11] included only randomized clinical trials that
compared acupuncture with sham acupuncture regardless
of the stages (acute, subacute, or chronic), types of stroke
(ischemic or hemorrhagic), and the number and regimen of
acupoints selected, and the results did not show a positive
eﬀect of acupuncture as a treatment for functional recovery
after stroke.
Scalp acupuncture (SA) is one of the several specialized
acupuncture techniques with a specific body location, in
which a filiform needle is used to penetrate specific stimu-
lation areas on the scalp. Although SA has been practiced
for thousands of years, SA develops very fast only in recent
decades [12]. During the 1970s, SA was developed as a
complete microacupuncture system based on the traditional
acupuncture science, modern anatomy, neurophysiology,
and bioholographic theory [12]. In 1984, a standard of
nomenclature for acupuncture points was developed and
reconfirmed in 1989, indicating 14 therapeutic lines or
zones based on a combination of the thoughts of the
diﬀerent schools of scalp acupuncture [12]. A Proposed
Standard International Acupuncture Nomenclature: 3.6 Scalp
acupuncture lines was formally published in 1991 by WHO
[13]. In modern time, SA is often applied for treatment
of central nervous system disorders and various acute or
chronic pains and has achieved specific curative eﬀects [14].
SA therapy for both ischemic stroke and hemorrhagic stroke
has been empirically established and widely used in clinics in
China [15, 16] and elsewhere in the world [17]. Although
SA is commonly used in the acute, recovery, and sequelae
stages of patients with ischemic stroke, the most important
period of recovery is at the acute and subacute stage during
the clinical course of ischemic stroke [18]. Therefore, the
objective of present systematic review was to assess clinical
eﬃcacy and safety of SA for acute ischemic stroke.
2. Methods
The PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) Statement guidelines was fol-
lowed during all stages of the design, implementation, and
reporting of this meta-analysis [19].
2.1. Eligibility Criteria. Only true randomised controlled
trials (RCTs) for evaluating the eﬀects of SA therapy on
acute ischemic stroke were included, regardless of blinding,
publication status or language. Quasi-RCTs were not con-
sidered such as using the admission sequence for treatment
allocation.
Participants with any age or sex and within 14 days of
onset of acute ischemic stroke were eligible. The diagnostic
criteria were adopted in accordance with national criteria
Diagnostic Essentials of Various Cerebrovascular Diseases in
1986 [20] or the revised version national criteria in 1995 [21].
Diagnosis of stroke had to be confirmed with CT/MRI scan
and haemorrhagic stroke excluded.
Studies were included if the intervention was SA therapy,
regardless of the sources or methods of stimulation (e.g.,
scalp penetration acupuncture or electrical stimulation),
the times of treatment, or the length of treatment period.
Acupoint selection was limited to the head; studies using ear
acupoints were excluded. The patients at the trial group were
given SA therapy plus the western conventional medication
(WCM) which was similar to the control group. WCM refers
to the combination of needed therapies of the following
aspects: (1) general supportive care mainly includes (A)
airway, ventilatory support and supplemental oxygen, (B)
cardiac monitoring and treatment, (C) temperature, (D)
blood pressure, (E) blood sugar, and (F) nutrition; (2)
specialized care mainly include a variety of measures to
improve cerebral blood circulation (such as antiplatelet
agents, anticoagulants, fibrinogen-depleting agents, volume
expansion, and vasodilators, except thrombolytic agents) and
neuroprotective agents; (3) treatment of acute complications
mainly includes (A) brain edema and elevated intracranial
pressure, (B) seizures, (C) dysphagia, (D) pneumonia, (E)
voiding dysfunction and urinary tract infections, and (F)
deep vein thrombosis. The intervention for control group
included only WCM treatments. Studies comparing SA
therapy to another form of acupuncture or combining SA
and acupuncture or Chinese herbal medicine were excluded.
The outcome measures were neurological deficit score,
the clinical eﬀective rate and adverse events at the end of
the treatment course. The neurological deficit score was
adopted based on the Modified Edinburgh-Scandinavian
Stroke Scale, which was recommended at the Second and
revised at the Fourth National Cerebrovascular Diseases
Conference in China in 1995 [21].
2.2. Information Sources and Search Strategy. Medical lit-
erature retrieval was performed by 2 investigators (WY
and WXM) in the following databases: CENTRAL (The
Cochrane Library 2012, Issue 1), PubMed (1950-December
2011), EMBASE (1980–2011), Chinese Biomedical Database
(1978–2011), Wanfang Database (1998–2011), and China
Hospital Knowledge Database (1979–2011). We used the
combining text terms and, where appropriate, MeSH
terms for scalp acupuncture (“scalp acupuncture” or
“head acupuncture” or “cranial acupuncture” or “cephalic
acupuncture” or “scalp electric acupuncture” or “scalp
penetration acupuncture”) and stroke (“cerebrovascular dis-
orders” or “cerebrovascular disease” or “stroke” or “brain
infarction” or “apoplexy”). The search terms were combined
with the “explode” feature. No limits were applied for
language and country.
2.3. Study Selection and Data Collection Process. Two inves-
tigators (WY and WXM) screened the titles and abstracts
to select potential references in an unblinded standardized
manner. Full articles for all potentially relevant studies were
retrieved. The 2 investigators then read the selected papers
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PRISMA 2009 flow diagram
Figure 1: Flow diagram for literature search.
independently and made a final selective decision. Disagree-
ments were settled through discussion or consultation with a
third author (ZGQ).
Two investigators (WY and WXM) independently col-
lected data on study characteristics, including patients,
methods, interventions, and outcomes, into a standardized
data extraction form for eligible studies. Reasons for the
exclusion of studies were recorded. Disagreements were
settled by discussion and consensus with a third member
(ZGQ).
2.4. Risk of Bias in Individual Studies. Two investigators
independently (WY and WXM) assessed risk of bias for each
included article, using the twelve criteria recommended by
the Cochrane Back Review Group [30]. Disagreements were
resolved through discussion with a third author (ZGQ).
2.5. Synthesis of Results. Heterogeneity between trial results
was tested using a standard chi-square test, and we also cal-
culated the I2 statistic. For continuous outcomes, weighted
mean diﬀerence (WMD) was calculated. For dichotomous
outcomes, relative risk (RR) and 95% confidence intervals
was calculated. Publication bias was assessed graphically
using a funnel plot. All statistical analyses were performed
by the Rev Man Version 5.0.
3. Results
3.1. Study Selection. We identified and selected 303 papers
by titles and abstracts. Among of them, 278 papers were
excluded because they were case reports, lacked a compar-
ison group, were not reports of clinical trials, or studies
not focused on the scalp acupuncture treatment of acute
ischemic stroke. Of the remaining 25 articles, 7 articles
were excluded because they reported a sub-acute ischemic
stroke with more than 14 days of onset or unclear durations;
5 articles were not RCTs or not real RCTs such as using
admission sequence for treatment allocation; 3 articles
evaluated SA plus body acupuncture or rehabilitation; 2
studies were suspected of being published more than once
by the authors or publishers. We attempted but failed finally
to contact the author for further information about the
allocation process. Eventually, 8 eligible studies [22–29] were
identified and included in this meta-analysis. The screening
process is summarized in a flow diagram (Figure 1).
3.2. Study Characteristics. The 8 studies were all conducted
by Chinese investigators and published between 1996 and
2011. Each study was performed in a single center. Five
hundred and thirty-eight participants of Chinese ethnicity
were included in the 8 studies, of whom 302 were male and
236 were female. The participants ranged in age from 38
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to 75 years old, while one study did not mention the age
range of participants [27]. One study was three-group design
study [28], in which both bilateral scalp penetration needling
and ipsilateral (disease-side) scalp penetration needling were
compared with the WCM control. The national diagnostic
criterion in 1995 was used in 7 studies; while the national
diagnostic criterion in 1986 was used in 1 study [22]. The
period of treatment varied from 10 days to 8 weeks. Clinical
eﬀective rate was observed in 4 studies and neurological
deficit score in 6 studies. Detailed characteristics of included
studies are listed in Table 1.
3.3. Results of Individual Studies. The twelve criteria recom-
mended by the Cochrane Back Review Group were used to
assess the risk of bias of each study. The number of criteria
complied varied from 4/12 to 7/12. All of the studies included
suggested randomization, but only 2 studies reported the
method of random sequences generation [26, 27]. No study
referred to allocation concealment, and blinding procedures.
2 studies reported intention-to-treat analyses and drop-out
data [24, 26]. All the studies presented selective reporting,
characterized similarity of baseline and reported the co-
intervention. Adequate and acceptable compliance seemed to
have been described in all of the included studies. Timing of
outcome assessments in all studies was similar. In general, all
8 RCTs were deemed to have an unclear risk of bias based on
the Cochrane Risk of Bias tool. The methodological quality
of each study is described in Table 2.
3.4. Synthesis of Results
3.4.1. Neurological Deficit Scores. Data extracted from 6
studies showed heterogeneity in the consistency of the trial
results (heterogeneity: chi-square = 14.02, P = 0.03, I2 =
77%). Thus, the random-eﬀects model should be employed
for statistical analysis. The combined eﬀects of 6 independent
trial results showed that SA therapy had further improved
the neurological deficit scores in patients with acute ischemic
stroke when compared with WCM control (n = 223, WMD:
−3.89, 95% CI: −5.36 to −2.43, z = 5.22, P < 0.00001),
Table 3. The funnel plot was asymmetric. There exists a
publication bias in the 6 independent trials (Figure 2).
3.4.2. The Clinical Eﬀective Rate. Data extracted from 4
studies showed homogeneity in the consistency of the trial
results (heterogeneity: chi-square = 0.57, P = 0.90; I2 =
0%). Thus, the fixed-eﬀects model should be employed for
statistical analysis. The combined eﬀects of 4 independent
trial results showed that SA therapy had further improved the
clinical eﬀective rate in patients with acute ischemic stroke
when compared with WCM control (n = 153, RR = 1.23,
95% CI, 1.11–1.37, z = 3.85, P < 0.01), Table 4.
3.4.3. Adverse Events. None of the trials reported adverse
eﬀects.
4. Discussion
4.1. Summary of Evidence. To our knowledge, this is the
first meta-analysis of SA therapy in the treatment of acute
ischemic stroke to date. 8 studies with 538 individuals
suﬀering from acute ischemic stroke were selected for present
meta-analysis. The main findings were that SA therapy can
further improve neurological deficit score and the clinical
eﬀective rate in patients with acute ischemic stroke when
compared with WCM control. However, the evidence is
insuﬃcient to warrant a clinical recommendation due to the
generally low methodological quality of the included studies.
In addition, there is no evidence available on safety because
none of the trials reported adverse eﬀects.
4.2. Limitations. In September 2004, the members of
the International Committee of Medical Journal Editors
(ICMJE) published a statement requiring that all clinical
trials must be registered in order to be considered for
publication [31]. Clinical trial registration will improve
research transparency and will ultimately strengthen the
validity and value of the scientific evidence base. However,
none of included studies had been registered.
There are several methodological limitations in the
primary studies. The included trials were of generally
poor methodological quality with regard to the method of
sample calculation, randomization, allocation concealment
and blinding of assessment. Moreover, no eligible sham SA-
controlled trials have been included and this may lead to an
increase in the risk of performance bias. Lack of blinding in
randomized trials has been shown to be associated withmore
exaggerated odds ratios by 9% on average for intervention
eﬀect [32].
The revised standards for reporting interventions in
clinical trials of acupuncture (STRICTA) [33] include 6 items
and 17 subitems, which set the reporting guidelines for the
acupuncture rationale, the details of needling, the treatment
regimen, other components of treatment, the practitioner
background, and the control or comparator intervention.
However, there were no suﬃcient reports on these items
in the included trials, especially for acupuncture techniques
such as the number of acupoints, the depth of insertion,
responses elicited, needle stimulation, and needle type, and
no trial mentioned practitioners’ background. A misleading
result could be exhibited if the treatment schedules were
inadequate or administered by unskilled practitioners.
The clinical heterogeneity would be very significant due
to the variations. Only 2 trials were conducted based on theA
Proposed Standard International Acupuncture Nomenclature
by WHO. 6 studies applied electrical stimulation with
variable frequency, while the other 2 studies used manual
stimulation of acupuncture needles. The diﬀerence between
the eﬀects of electroacupuncture and manual acupuncture
could not be determined. The available data from the
included trials were only secondary outcomes, and none used
primary outcomes such as death or dependency for com-
parison. Duncan et al. [34] recommended that acute stroke
trials should include extended/instrumental activities and
advanced mobility as components of the primary outcome
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Table 2: The included trials scored according to the risk of bias criteria.
A B C D E F G H I J K L
Tang and Sun 1996 [22] − − − − − ? + ? + + − +
Yu et al. 2004 [23] − − − − − + + ? + + + +
Wei et al. 2005 [24] − − − − − − − ? + + + −
Xu et al. 2007 [25] − − − − − + + ? + + + +
Chen and Jing 2008 [26] + − − − − − + ? + + + +
Yu et al. 2010 [27] + − − − − + + ? + + + +
Zhang et al. 2011 [28] − − − − − + + ? + + + +
Zhu and Huang 2011 [29] − − − − − + + ? + + + +
A: adequate sequence generation; B: concealment of allocation; C: Blinding (patient); D: blinding (investigator); E: blinding (assessor); F: intention-to-treat
analysis (ITT analysis); G: incomplete outcome data addressed(drop-outs); H: free of selective reporting; I: similarity at baseline; J: cointerventions constant;
K: compliance acceptable; L: timing outcome assessments similar. +: Yes, −: No, ?: Unclear.
Table 3: Forest plot of comparison: scalp acupuncture versus western conventional medicines: neurologic deficit scores.
Study or
subgroup
Experimental Control Weight Mean diﬀerence IV,
Random, 95% CI
Mean diﬀerence IV,
Random, 95% CIMean SD Total Mean SD Total
Wei et al. 2005
[24]
18.53 6.8 36 23.9 6.77 36 12.8% −5.37 [−8.50,−2.24]
0 50 100
Favours 
experimental
Favours 
control
−100 −50
Xu et al. 2007
[25]
13.24 1.87 61 17.21 1.23 61 29.6% −3.97 [−4.53,−3.41]
Yu et al. 2004 [23] 9.43 3.76 30 11.7 3.63 30 20.5% −2.27 [−4.14,−0.40]
Yu et al. 2010 [27] 13.2 6.486 20 18.4 9.034 20 7.0% −5.20 [−10.07,−0.33]
Zhang et al.
2011b [28]
14 7.1 23 18.4 8.7 23 7.6% −4.40 [−8.99, 0.19]
Zhang et al.
2011a [28]
9.5 5.6 23 18.4 8.7 23 8.6% −8.90 [−13.13,−4.67]
Zhu and Huang
2011 [29]
7.55 5.59 30 8.3 4.8 20 13.9% −0.75 [−3.65, 2.15]
Total (95% CI) 223 213 100.0% −3.89 [−5.36,−2.43]
Heterogeneity: Tau2 = 1.80; Chi2 = 14.02, df = 6 (P = 0.03); I2 = 57%
Test for overall eﬀect: z = 5.22 (P < 0.00001)
0 50 100
0
1
2
3
4
5
MD
SE
 (
M
D
)
−100 −50
Figure 2: Funnel plot of comparison: scalp acupuncture versus western conventional medicines: neurologic deficit scores.
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Table 4: Forest plot of comparison: scalp acupuncture versus western conventional medicines: the clinical eﬀective rate.
Study or subgroup
Experimental Control Weight Risk ratio M-H,
Fixed, 95% CI
Risk ratio
M-H, Fixed, 95% CIEvents Total Events Total
Chen and Jing 2008
[26]
28 30 21 30 18.7% 1.33 [1.04, 1.72]
Favours 
experimental
Favours 
control
0.01 0.1 1 10 100
Tang and Sun 1996
[22]
28 30 25 33 21.2% 1.23 [0.99, 1.53]
Wei et al. 2005 [24] 21 32 17 31 15.4% 1.20 [0.80, 1.80]
Xu et al. 2007 [25] 60 61 50 61 44.6% 1.20 [1.06, 1.36]
Total (95% CI) 153 155 100.0% 1.23 [1.11, 1.37]
Total events 137 113
Heterogeneity: Chi2 = 0.57, df = 3 (P = 0.90); I2 = 0%
Test for overall eﬀect: z = 3.85 (P = 0.0001)
measure, with outcome assessment being undertaken at 6
months. Therefore, using primary outcome such as death
or dependency will provide useful data for this therapy.
In addition, the clinical eﬃcacy, which was classified as
cure, markedly eﬀective, eﬀective, and ineﬀective, is not
internationally recognized, and it is not accurate for the
assessment of the eﬀect.
Researchers participating in a clinical trial must report all
adverse events. However, none of the included trials reported
whether any adverse events relevant to SA were apparent in
patients with acute ischemic stroke.
The funnel plot asymmetry suggests the possibility of
publication bias. In addition, language bias may exist because
all included trials were published in Chinese. Vickers and col-
leagues [35] indicated that some Asian countries including
China publish unusually high proportions of positive results.
Although great eﬀorts were made to retrieve all trials on the
subject, we still could not exclude the possibility that studies
with negative findings remain unpublished.
4.3. Implication for Practice. From the evidence available in
the present systematic review, there is no conclusive evidence
for the routine use of SA for acute ischemic stroke. Thus,
the continuing and increasing limited evidence to support
the application of SA is noteworthy. However, SA appears
to be able to improve neurological deficit score and the
clinical eﬀective rate when compared with WCM control.
With the widespread use of SA, we suggested the onus being
on clinicians to provide the clear evidence for its use.
Acupuncture appears to be a safe treatment when used
in the acute phase of stroke, with severe adverse events
occurring very rarely [36]. A NIH consensus report also
stated that one of the advantages of acupuncture was that the
incidence of adverse eﬀects is substantially lower than that of
many other accepted medical interventions [37]. However,
various types of acupuncture-related adverse events have
been reported in China [38] and other countries [39]. Owing
to most of acupuncture-related adverse events as a result
of inappropriate technique [38], SA may be also considered
inherently safe in the hands of well-trained practitioners.
Unfortunately, no evidence is available from present studies
to support or refute the safety of SA.
4.4. Implication for Research. Further trials should improve
in the methodological quality of RCTs as follows: (1) all clin-
ical trials registered according to ICMJE statement [31]; (2)
sample size estimated by statistical calculation; (3) reporting
of the adequate generation of the allocation sequence and
adequate allocation concealment; (4) a clear description
of the blinding; (5) use of sham SA-control; (6) a clear
definition of the modality of SA, especially the international
standard of SA lines by WHO; (7) the skilled practitioners
should be selected to perform the SA manipulation and keep
the consistency for all the time, and select suitable number
of treatment sessions and frequency of treatment; (8) the
balance of basic demographic data and baseline disease
staging; (9) use of standard and validated outcomemeasures,
and reporting important clinical outcome measures such
as death, dependency, and quality of life for at least 6-
month followup. Psychometric properties include validity,
reliability, and sensitivity to change. An assessment tool
should be scientifically sound in terms of three basic
psychometric properties: reliability, validity, and respon-
siveness [40]. Thus, using standardised outcome measures
with acceptable psychometric properties is needed in future
studies; (10) SA-related adverse events should be rigorously
assessed by standardized monitoring and an eﬀective self-
report system; and (11) the trials must be reported by using
Revised standards for reporting interventions in clinical trials
of acupuncture (STRICTA) [33] and some additional key
elements in the reporting about acupuncture trials [41].
5. Summary
Based on the results of present systematic review, SA
is significantly eﬀective in improving neurological deficit
score and clinical eﬀective rate when compared with WCM
control, though the beneficial eﬀect from SA is possibly
overvalued because of generally low methodology of the
included trials. No adverse events were documented in these
8 Evidence-Based Complementary and Alternative Medicine
RCTs studies. More trials should be thoroughly focused on
the experimental design and monitoring of adverse events.
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